BRIEF published on 12/11/2025 at 23:05, 3 months 27 days ago Xenetic Biosciences ajourne son assemblée générale annuelle des actionnaires de 2025. Instructions De Vote Quorum Biosciences Xénétiques Assemblée Générale Des Actionnaires Ajournement De 2025
BRIEF published on 12/11/2025 at 23:05, 3 months 27 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 3 months 27 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 4 months 18 days ago Xenetic Biosciences étend sa collaboration avec Scripps Research Biopharmaceutique Traitement Du Cancer DNase I Thérapie CAR-T Recherche Scripps
BRIEF published on 11/19/2025 at 14:50, 4 months 18 days ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 4 months 18 days ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 4 months 24 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
BRIEF published on 11/13/2025 at 14:50, 4 months 24 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 4 months 24 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 5 months 28 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
Published on 04/08/2026 at 08:05, 2 hours 3 minutes ago Tocvan Announces Addition of Second Drill Rig and Accelerates High-Priority Drill Targets at Flagship Gran Pilar Gold-Silver Project
Published on 04/08/2026 at 02:50, 7 hours 18 minutes ago Panther Minerals Announces Appointment of Rick Mah to Board of Directors
Published on 04/08/2026 at 01:35, 8 hours 33 minutes ago Polaris Renewable Energy Announces Q1 2026 Investor Call Details
Published on 04/08/2026 at 00:40, 9 hours 28 minutes ago Relevant Gold Announces Initial Closing of Strategic Financing
Published on 04/08/2026 at 00:10, 9 hours 58 minutes ago Trans Canada Gold Completes the Acquisition of the Harrison Lake District Scale Gold Property and First Tranche of the Non-Brokered Private Placement
Published on 04/08/2026 at 09:23, 45 minutes ago IBU-tec advanced materials AG: 2025 annual financial statements presented and dividend proposal of EUR 0.12 per share
Published on 04/08/2026 at 09:10, 58 minutes ago Reolink Announces Official Integration with Homey to Elevate Smart Home Automation
Published on 04/08/2026 at 09:05, 1 hour 3 minutes ago Lenzing Commissions 14 MW Power‑to‑Heat Facility, Strengthening Grid Stability and Heat Management
Published on 04/08/2026 at 09:00, 1 hour 7 minutes ago Original-Research: EPH Group AG (von NuWays AG): BUY
Published on 04/08/2026 at 09:00, 1 hour 7 minutes ago Original-Research: ASMALLWORLD AG (von NuWays AG): BUY
Published on 04/08/2026 at 08:30, 1 hour 38 minutes ago Edenred Mobility and Electra form a strategic partnership to accelerate the electrification of commercial fleets in France
Published on 04/08/2026 at 08:30, 1 hour 38 minutes ago Edenred Mobilité et Electra nouent un partenariat stratégique pour accélérer l’électrification des flottes professionnelles en France
Published on 04/07/2026 at 18:00, 16 hours 8 minutes ago LDC : Chiffre d’affaires du 4 ème trimestre 2025-2026. Solide croissance du chiffre d’affaires au 4ème trimestre 2025-2026 et révision à la hausse des objectifs.
Published on 04/07/2026 at 17:57, 16 hours 11 minutes ago Peugeot Invest publishes its 2025 Universal Registration Document
Published on 04/07/2026 at 17:57, 16 hours 11 minutes ago Mise à disposition du Document d’enregistrement universel 2025
